Once-weekly oral antidiabetic agent and treatment satisfaction

Re: Handelsman Y, Lauring B, Gantz I, et al. A randomized, double-blind, non-inferiority trial evaluating the efficacy and safety of omarigliptin, a once-weekly DPP-4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Curr Med Res Opin 2017: published online 26 May 2017, doi: 10.1080/03007995.2017

Mitsuyoshi TakaharaMitsuyoshi Takahara, Department of Diabetes Care Medicine, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka565-0871, JapanCorrespondence[email protected]

http://orcid.org/0000-0001-5105-041X

Toshihiko ShiraiwaShiraiwa Medical Clinic, Kashiwara City, Japan

Naoto KatakamiDepartment of Metabolic Medicine, Osaka University Graduate School of Medicine, Suita City, Japan

Taka-aki MatsuokaDepartment of Metabolic Medicine, Osaka University Graduate School of Medicine, Suita City, Japan

Iichiro ShimomuraDepartment of Metabolic Medicine, Osaka University Graduate School of Medicine, Suita City, Japan

References

Handelsman Y, Lauring B, Gantz I, et al. A randomized, double-blind, non-inferiority trial evaluating the efficacy and safety of omarigliptin, a once-weekly DPP-4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Curr Med Res Opin 2017: published online 26 May 2017, doi: 10.1080/03007995.2017.1335638
PubMed Web of Science ®Google Scholar
Takahara M, Shiraiwa T, Ogawa N, et al. Patient perspectives on combination therapy of a once-weekly oral medication plus daily medication for lifestyle-related chronic diseases. Intern Med 2017;56:615-20
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Once-weekly oral antidiabetic agent and treatment satisfaction

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Once-weekly oral antidiabetic agent and treatment satisfaction

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date